METHODS:
• The following databases were searched systematically for randomized-controlled studies:
-PubMed, Health Technology Assessment Database, NHS Economic Evaluation Database, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, DAHTA-Datenbank, PSYNDEX and PsycINFO. 
PICO criteria Definition
Patient "Alzheimer's Disease"; "Alzheimer"; "Alzheimer type dementia"
Intervention
Drug treatment -Rivastigmine, Galantamine, Memantine, Donepezil Psychiatric-Therapeutic treatment Other medical and Therapeutic treatment Diagnostics
Comparison

Other forms of dementia
Outcomes
Therapeutic treatment options Morbidity & mortality Complications
-Search terms:  Therapies: Rivastigmine, Galantamine, Memantine, Donepezil  Indication: "Alzheimer's Disease"; "Alzheimer"; "Alzheimer type dementia"  Extraction: Only efficacy parameters  In order to catch all relevant articles the following inclusion criteria will be applied:  Time: all articles between 2000 until 2014  Language: English, German • For the abstracts that met the pre-defined inclusion criteria, full text articles were obtained. The abstracts that did not meet the search criteria were excluded. • Based on these full text reports it was evaluated whether each study meets the selection criteria.
RESULTS:
• After elimination of duplicates the search yielded 418 articles of which another 299 were excluded based on the title selection; after abstract review (exclusion n=37), 82 articles have been reviewed in full text which were also deemed to be relevant based on the research question.
• For donepezil 24 clinical studies have been identified: -10 studies were identified without an active comparator:  6 trials analyzed donepezil without a comparator (single-arm study). Out of those two were extension studies of RCTs, two were single-arm studies, one was a trial in a naturalistic environment and one was a meta-analysis. Donepezil was more efficacious in all settings but the Mini-Mental-State-Examination (MMSE) score in the naturalistic setting was not significant.  Three studies were RCTs analyzing the 10mg versus the 23mg dosage of donepezil. Inconsistent results were reported whereas the higher dose was more efficacious in most outcomes measures.  One study analyzed the dosages of 5mg and 10mg vs placebo and concluded that donepezil is more efficacious.
-8 studies compared donepezil versus placebo with inconsistent results (defined as significant and non-significant primary endpoints in studies with the same therapeutic option).  In the MMSE score donepezil was more efficacious in all RCTs but not in the community based RCT.  All other measures were inconsistent. -6 studies analyzed donepezil versus other active and approved comparators  In a study analyzing Donepezil vs memantine vs Donepezil + memantine vs placebo the authors showed that the two monotherapies were more efficacious than placebo and the combination was not more efficacious than the monotherapies alone.  Two studies compared galantamine versus donepezil versus rivastagmine with inconsistent results. Most of the scores showed no significant difference.  One study analysed donepezil with and without the addition of memantine and showed a significant benefit for the combination therapy.
• For galantamine 10 clinical studies have been identified: -Three single-arm studies were identified showing the benefits of galantamine over time.
-Five studies compared galantamine versus placebo and showed consistent benefits of galantamine. The only outcomes score which showed no difference to placebo was the MDS-ADL score. -One meta-analysis has shown a non-significant trend towards a better ADAS-Cog score for galantamine compared to donepezil.
-One study has shown that the non-interrupted administration of galantamine is more efficacious than interruption in treatment • For memantine 14 clinical studies have been identified:
-One study analyzed the benefits of different dosage applications showing that there is no difference in terms of outcomes.
-One study was an open-label extension single-arm after previous placebo treatment and showed that memantine improved the outcomes in terms of ADCS-ADL, CIBIC+ and SIB. -Furthermore it was shown that the addition of rivastigmine to memantine was not linked to an improved efficacy outcome.
-Overall 11 studies compared memantine against placebo. Results were inconsistent.
• For rivastigmine 18 clinical studies have been identified:
-Two single-arm studies were performed consistently reporting better efficacy parameters for rivastigmine.
-One meta-analysis was confirming the findings of rivastigmine being more efficacious.
-Three publications focused on the differences in terms of dosing (13.3 mg versus 9.5mg) and reporting the higher dose being more efficacious. -The 13.3mg dosage was also shown to be more efficacious in comparison to the 4,5mg dosage.
-Two studies showed that both formulations (capsule and patch) are better compared to placebo -No difference was shown when comparing rivastigmine against donepezil in one study and one trial was showing a significant benefit of rivastigmine over donepezil. -When comparing rivastigmine transdermal patches with or without concomitant memantine the combination has not shown to be more efficacious. -The ADAS-cog was improved with rivastigmine treatment when compared to historical data.
-Additionally there were four trials comparing rivastigmine to placebo consistently showing a significant benefit of rivastigmine.
• Two studies analyzing ChEI against each other -Furthermore there were two studies (one RCT and one real life observational single-arm trial) analyzing the different ChEI therapies (donepezil, galantamine, rivastigmine) against each other. Both studies showed no significant differences between those therapies.
CONCLUSIONS:
• In comparison the clinical evidence seems to look varying dependent on the patient characteristics, study duration, and severity of disease.
• Appropriate evidence assessment for the approved AD treatments requires clinical expertise and close review of the study characteristics.
• Next steps: Comparing the study characteristics preparing a network meta-analysis and extracting the safety information of the identified studies. 
